About two billion people are latently infected with Mycobacterium tuberculosis (Mtb), which can reside in multiple organs, including the lymphatics. The risk of latent Mtb infection (LTBI) reactivation increases with immunosuppression, such as HIV coinfection, yet the immunological correlates that maintain LTBI remain largely elusive. Using a mouse model of contained lymphatic Mtb infection we dissect the drivers of containment versus reactivation. We show that immunosuppression-induced dissemination of lymphatic Mtb and ensuing progressive disease can be prevented by vaccination with BCG or recombinant BCG even in the absence of CD4+ T cells. Multi-parameter imaging, spatial transcriptomics and network analysis reveal that anti-CD4-mediated immunosuppression triggers distinct repositioning of non-CD4 immune cells at the edge of TB lesions in cervical lymph nodes. Although B cell numbers increase, they prove dispensable for Mtb containment during CD4+ T cell loss. Using immune cell-deficient mice, cell depletion and adoptive transfers, we reveal that CD8+ T cells mediate vaccination-induced prevention of Mtb dissemination in the absence of CD4+ T cells, informing LTBI management in immunocompromised individuals.
A 3-week delay in the onset of T cell immunity to Mycobacterium tuberculosis ( Mtb ) infection compromises lung bacterial control, resulting in tuberculosis (TB). Restoring T cell function is a priority. We identified how airway CD44 + CD62L − KLRG1 + CD8 + effector memory T cells (T EM ) in the lung enhance mycobacterial clearance via the spleen. Unexpectedly, a secondary immune response following repeated exposure of mice to Bacille Calmette-Guérin generated lower numbers of T EM versus primary. Paradoxically, lower numbers correlated with faster bacterial clearance, due to enhanced trafficking of secondary T EM to the spleen, where they responded to antigen. Further, secondary T EM recruited dendritic cells, which accelerated bacterial translocation from the lung to the spleen. Treating mice with a threshold number of airway-derived secondary T EM significantly reduced Mtb burden in the lung and spleen. Notably, Mtb killing was expedited by at least 15 days. Repeated antigen encounter bypassed priming requirements and enhanced T EM durability, uncovering a spleen-centered protective mechanism with implications for improved TB vaccines and therapies.
Pulmonary vaccination has been proposed as a strategy to improve protection against tuberculosis, due to the generation of immune cells that more efficiently survey and eliminate infected cells within the lung. However, uncontrolled replication and excessive inflammation associated with mucosal delivery of live-attenuated vaccines highlight the need for alternative strategies that balance efficacy and safety. Here, we describe a prime-and-pull vaccination approach in which systemic immunity is established by subcutaneous BCG vaccination, followed by the induction of local lung immunity through mucosal delivery of lipid nanoparticle–formulated multi-antigen mRNA. Proof-of-concept studies using a model antigen demonstrated the induction of polyfunctional antigen-specific T cells in the lung with minimal inflammatory cell infiltration, compared with mucosal BCG vaccination. Eight Mycobacterium tuberculosis - and BCG-derived proteins were subsequently selected to generate four multi-antigen mRNA constructs. In vivo vaccination and challenge experiments demonstrated that this prime-and-pull strategy is well tolerated and confers protective immunity against tuberculosis in a murine model. Collectively, these data support a modular mRNA-based prime-and-pull vaccination strategy as a translational approach that bridges the improved immunogenicity and efficacy of mucosal BCG vaccination with the safety profile of parenteral BCG administration. Graphical
Background: Tuberculosis remains a leading cause of death from infectious disease worldwide, and the limited efficacy of Bacille–Guérin (BCG) vaccination against adult pulmonary tuberculosis highlights the need for improved vaccines. Although mucosal BCG vaccination enhances lung immunity, safety concerns associated with pulmonary delivery of live-attenuated mycobacteria limit its clinical translation.Methods: We developed a prime-and-pull vaccination strategy in which systemic immunity was established by subcutaneous BCG vaccination followed by the induction of local lung immunity through mucosal administration of lipid nanoparticle-formulated multi-antigen mRNA. Immunogenicity, inflammatory responses, safety, and protective efficacy were evaluated in murine models of tuberculosis.Findings: Pulmonary delivery of lipid nanoparticle-formulated mRNA induced antigen-specific polyfunctional T-cell responses in the lung while eliciting minimal inflammatory cell infiltration compared with mucosal BCG vaccination. Following BCG priming, the multi-antigen mRNA boost generated robust local immune responses and was well tolerated. In a murine Mycobacterium tuberculosis challenge model, the prime-and-pull strategy conferred protection comparable to mucosal BCG vaccination while avoiding the safety concerns associated with pulmonary administration of live BCG.Interpretation: These findings demonstrate that mRNA-mediated pulmonary immune boosting following parenteral BCG vaccination is a promising and modular strategy to enhance tuberculosis vaccine efficacy while preserving the established safety profile of systemic BCG vaccination. This approach provides a translational platform for next-generation tuberculosis vaccines.